Spruce Biosciences logo

Spruce BiosciencesNASDAQ: SPRB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

09 October 2020

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$22.00 M
-90%vs. 3y high
25%vs. sector
-vs. 3y high
-vs. sector
-87%vs. 3y high
25%vs. sector
-95%vs. 3y high
40%vs. sector

Price

after hours | Fri, 01 Nov 2024 22:23:17 GMT
$0.53-$0.01(-2.28%)

Dividend

No data over the past 3 years
$1.61 M$1.49 M
$1.61 M-$9.18 M

Analysts recommendations

Institutional Ownership

SPRB Latest News

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
accesswire.com03 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Take Part
accesswire.com02 November 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
businesswire.com28 October 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 3:30 p.m. ET. Interested parties can access the live webca.

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
accesswire.com27 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
accesswire.com26 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
accesswire.com19 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Shareholders To Reach Out
accesswire.com18 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
accesswire.com13 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Shareholders To Reach Out
accesswire.com12 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
accesswire.com08 October 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / October 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

What type of business is Spruce Biosciences?

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

What sector is Spruce Biosciences in?

Spruce Biosciences is in the Healthcare sector

What industry is Spruce Biosciences in?

Spruce Biosciences is in the Biotechnology industry

What country is Spruce Biosciences from?

Spruce Biosciences is headquartered in United States

When did Spruce Biosciences go public?

Spruce Biosciences initial public offering (IPO) was on 09 October 2020

What is Spruce Biosciences website?

https://www.sprucebiosciences.com

Is Spruce Biosciences in the S&P 500?

No, Spruce Biosciences is not included in the S&P 500 index

Is Spruce Biosciences in the NASDAQ 100?

No, Spruce Biosciences is not included in the NASDAQ 100 index

Is Spruce Biosciences in the Dow Jones?

No, Spruce Biosciences is not included in the Dow Jones index

When was Spruce Biosciences the previous earnings report?

No data

When does Spruce Biosciences earnings report?

The next expected earnings date for Spruce Biosciences is 13 November 2024